+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.

Age: 18Years +All GendersPhase Not Applicable
45 locations
C

Actively Recruiting

Researchers are studying chronic pain, a condition affecting about 20% of adults and half of elderly people, with significant impacts on work and quality of life. The research aims to better understand and follow chronic pain patients over time using digital tools, creating a large group of patients for detailed study and personalized care. The study is observational and involves multiple pain clinics to gather real-life data for research and healthcare improvement. The study uses e-DOL, an electronic health tool including a smartphone app for patients and a web platform for healthcare providers in pain clinics. This tool collects repeated questionnaires, weekly status updates, educational materials, and chatbot interactions to gather comprehensive information on pain and its effects. Data will also be linked with French health insurance records to understand patient comorbidities and healthcare use. Participants will be adults with chronic pain who regularly use smartphones and agree to participate. The study will follow at least 5,000 patients across 20 clinics for 24 months, collecting detailed data on their pain experiences, sleep, activity, emotional health, and treatments. Researchers will analyze this large dataset over five years to characterize chronic pain and its impacts, monitoring patients remotely through the app and linked healthcare records.

Age: 18Years +All Genders
22 locations
S

Actively Recruiting

Researchers are evaluating the effect of digital monitoring of self-reported symptoms on how treatment is managed in patients with advanced clear cell renal cell carcinoma RCC receiving cabozantinib plus nivolumab. This Phase 4 study focuses on the first three months of combined treatment in a real-life setting, aiming to improve patient care by adjusting treatments based on weekly symptom reports. The study is sponsored by Centre Francois Baclesse. Participants receive cabozantinib orally once daily and nivolumab intravenously every two weeks as prescribed in the labeling. During this treatment, a digital monitoring system collects weekly patient reports on treatment tolerance. The system uses an algorithm to classify patients risk levels and generate alerts that may lead to treatment adjustments. This digital telemonitoring platform supports early detection of adverse events related to the combination therapy. Participants will be involved in regular weekly self-reporting of symptoms through a mobile digital device for up to six months. Researchers will assess treatment management adjustments within the first three months and track symptom evolution, fatigue, quality of life, anxiety, depression, pain, and adverse reactions over six months. The study evaluates the feasibility of this digital approach to follow-up and the impact of alerts generated by the monitoring platform on patient management and outcomes.

Age: 18Years +All GendersPhase 4
19 locations
P

Actively Recruiting

Researchers are studying how to adjust the dose of fluoropyrimidine chemotherapy based on uracilemia levels in patients with DPD deficiency who have gastrointestinal cancers. This phase II multicenter trial aims to find the best dose reduction strategy to reduce side effects while treating digestive cancers. The main question is which dose reduction is needed for patients with this enzyme deficiency. Participants will receive chemotherapy with doses adjusted according to their uracilemia level. Patients with low uracilemia <16 ngmL will get the full dose, while those with higher levels will receive varying dose reductions or random assignments between 25% and 50% reductions depending on their uracilemia range. Treatments include the FOLFOX or CAPOX chemotherapy regimens, given in cycles every 2 to 3 weeks. During the study, participants will visit the clinic every 2 to 3 weeks for checkups and tests to monitor side effects and treatment response. Researchers will measure the occurrence of serious blood and gastrointestinal toxicities after two treatment cycles and track dose adjustments, toxicity, and survival outcomes over several months and years. The study involves close monitoring of health and treatment effects for up to three years, depending on cancer stage.

Age: 18Years +All GendersPhase 2
41 locations
S

Actively Recruiting

Researchers are evaluating the effects of American ginseng combined with vitamin C from Camu Camu berries on fatigue in patients treated for localized breast or gynecological cancer. This multicenter randomized trial aims to assess the safety and efficacy of the dietary supplement Qiseng in improving cancer-related fatigue. The study is randomized, double-blind, and placebo-controlled, led by the Centre Francois Baclesse. Participants receive either Qiseng, containing 200 mg of P. quinquefolius extract 30 mg ginsenosides plus 30 mg vitamin C, or a placebo made of microgranules without active extracts. Both groups take 2 capsules daily for 8 weeks. The trial includes detailed monitoring of fatigue and other quality-of-life aspects during and after treatment. During the study, participants will have their fatigue levels assessed after 1 week and 4 weeks following the 8-week treatment. Researchers will also evaluate other fatigue dimensions, treatment-related side effects, quality of life, anxiety, cognitive function, physical activity, sleep quality, and treatment acceptability at multiple timepoints. The study spans approximately 12 weeks with close follow-up for safety and outcome measurement.

Age: 18Years +FEMALEPhase Not Applicable
10 locations
E

Actively Recruiting

Researchers are evaluating the performance and safety of a mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert in people aged 12 and older who have acute rhinitis with nasal obstruction. This observational study focuses on how well the spray works over a 7-day period for conditions like infectious rhynopharyngitis, rhinosinusitis, and allergic rhinitis affecting the nasal passages. Participants will use the seawater spray during the study and their experiences will be recorded. The study does not involve multiple treatment groups or placebo comparison. The sprays effects are assessed at several points, including immediately after use, after 3 days, and after 7 days. Researchers will monitor symptoms such as nasal obstruction relief, nasal secretion thinning, nasal cavity cleansing, and patient satisfaction. During the 7 days of spray use, participants will complete questionnaires about their symptoms and feelings of relief or irritation each day. The study measures the sprays performance, any adverse events, device issues, and the overall impact on quality of life. Participants safety and satisfaction with the spray will also be tracked, with evaluations mainly focused on the first week of use.

Age: 12Years +All Genders
3 locations
N

Actively Recruiting

Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.

Age: 18Years +All GendersPhase Not Applicable
83 locations
E

Actively Recruiting

Researchers are evaluating whether certain women with early-stage, low-risk hormone receptor-positive and HER2-negative breast cancer can safely skip hormone therapy after surgery and possibly radiation therapy. This study focuses on postmenopausal women aged 60 and older with small tumors that have a very low risk of recurrence. It aims to compare outcomes for those who avoid hormone treatment with others who received standard hormone therapy in a different study, while also assessing their risk of cancer return, cardiovascular and bone health, and quality of life. Participants will not receive any hormone therapy such as tamoxifen or aromatase inhibitors during the study. All participants must have had surgery to remove the tumor, and if breast-conserving surgery was performed, they should have received or be scheduled for radiotherapy within three months after surgery. No chemotherapy will be given or planned. The study will enroll participants for two years, followed by up to five years of monitoring after the last person joins to observe long-term cancer recurrence and other health outcomes. During the study, participants will attend scheduled visits for medical evaluations, laboratory tests, and complete quality of life and mood questionnaires at baseline, 6 months, 1 year, and annually thereafter until five years after the last participant is enrolled. Researchers will monitor cancer recurrence rates, bone and cardiovascular events, and overall survival. This comprehensive follow-up aims to understand the effects of avoiding hormone therapy on both cancer outcomes and participants wellbeing over time.

Age: 60Years +FEMALEPhase 2
41 locations
M

Actively Recruiting

Researchers are evaluating the plasma levels of various multikinase inhibitors MKIs in patients with advanced digestive cancers such as gastrointestinal stromal tumor GIST, metastatic colorectal cancer mCRC, hepatocellular carcinoma HCC, gastroenteropancreatic neuroendocrine tumor gepNET, and pancreatic neuroendocrine tumor pNET. This Phase IV, national, multicenter, open-label, multi-cohort interventional study aims to determine the optimal dose of these MKIs for each patient in the future. Participants receive treatment according to standard care for their specific cancer and MKI drug Regorafenib for mCRC, GIST, and HCC Everolimus for gepNET Sunitinib for pNET and GIST Cabozantinib for HCC and the combination of Encorafenib and Cetuximab for mCRC. Blood samples are collected at baseline, one month, and two months after treatment starts, as well as during adverse events or if disease progresses, to measure drug plasma concentrations and build pharmacokinetic models. During the study, participants are monitored through blood draws and tumor evaluations following local clinical practice. Researchers measure trough drug concentrations throughout treatment, along with progression-free survival, overall survival, response rates, disease control, and safety including drug toxicity for up to four years. This long-term follow-up helps understand treatment effects and drug exposure in advanced digestive cancer patients.

Age: 18Years +All GendersPhase Not Applicable
29 locations
P

Actively Recruiting

Researchers are studying advanced cancer of the stomach and the gastro-esophageal junction, a serious disease with low survival rates. The trial focuses on patients whose cancer has progressed after two or three prior treatments. The study aims to evaluate whether combining the oral drug trifluridinetipiracil with the anti-angiogenic drug fruquintinib can improve survival compared to trifluridinetipiracil alone. This international Phase III trial builds on recent advances in immunotherapy and targeted therapies for this cancer type. Participants are randomly assigned to one of two groups. One group receives trifluridinetipiracil alone in 28-day cycles, taking the drug by mouth twice daily on Days 1 to 5 and Days 8 to 12 with rest days in between, repeated every 4 weeks. The other group receives the same trifluridinetipiracil schedule plus fruquintinib by mouth once daily for 21 days each cycle. Treatment continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants undergo regular assessments to monitor overall survival up to 18 months after starting treatment. Researchers will also measure progression-free survival during this period. Patients will have tumor evaluations, laboratory tests, and monitoring for treatment side effects. Participants must meet specific health criteria and agree to biological studies. The study provides close follow-up to evaluate the effects of the treatments over time.

Age: 18Years +All GendersPhase 3
64 locations